FindTrial
Sign In

Feasibility of using quantitative assessment using contrast-enhanced ultrasound evaluation of early effect of immunological therapy for colorectal liver metastases

Feasibility of using quantitative assessment using contrast-enhanced ultrasound evaluation of early effect of immunological therapy for colorectal liver metastases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048066
Enrollment
Unknown
Registered
2021-06-29
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal liver metastases

Interventions

Case series:Nil

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All patients with advanced CRC liver metastasis confirmed by pathology as MSI-H/ DMMR, and there were evaluable liver metastases; 2. All patients received first-line immunotherapy regimen; 3. Aged 18 to 80 years; 4. Complete clinical data.

Exclusion criteria

Exclusion criteria: 1. The expected survival time of > was 3 months; 2. Complicated with dysfunction of heart, liver, kidney and other vital organs; 3. Complicated with other malignant tumors; 4. Mental disorders; 5. Allergic to immune drugs; 6. Pregnant and lactating.

Design outcomes

Primary

MeasureTime frame
Peak intensity, PI;Time to peak, TTP;Area under curve, AUC;Slope of rise, Pw;—

Countries

China

Contacts

Public ContactFang Lingyun

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

fangly@hust.edu.cn+86 18207177828

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026